Journals / Bağcılar Tıp Bülteni / 2022 / Cilt: 7 - Sayı: 1

Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study

ICSI Uygulanan Polikistik Over Sendromlu Hastalarda Rekombinant FSH ve Yüksek Saflaştırılmış Üriner FSH’nin Etkinliklerinin Karşılaştırılması

Pages
63–69
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI).
📊
Key Findings & Data:A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol.
💡
Conclusion & Impact:Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, in vitro fertizilization (IVF) Unit. A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol. The main outcome measures were the number of mature oocytes retrieved, embryo quality, pregnancy rates, implantation rates. Results: The number of mature oocytes retrieved, fertilization rates, the number of cryopreserved embryos were significantly higher in r-FSH group (p=0.024, p=0.023, p=0.026 respectively) while the total dose of FSH used was significantly lower in the same group (p=0.023). Pregnancy rates, clinical pregnancy rates were higher in r-FSH group although not statistically significant (52.2% versus 35.6%, p=0.11, 37% versus 28.9%, p=0.41 respectively). Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups. Conclusion: r-FSH is superior than HP-uFSH in PCOS regarding fertilization rates, the number of mature oocytes retrieved and cryopreserved embryos, pregnancy rates although overall therapy costs per clinical pregnancy are higher.

Özet

Amaç: ICSI uygulanan PCOS hastalarında rekombinant FSH (r-FSH) ve yüksek oranda saflaştırılmış üriner FSH’nin (HP-uFSH) etkinliğini ve güvenliğini karşılaştırmaktır. Yöntem: Kocaeli Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı Tüp Bebek Ünitesi’nde yürütülen prospektif randomize bir çalışmadır. ICSI uygulanan toplam 91 PCOS hastası, bir GnRH antagonist protokolü ile r-FSH (n=46) ve HP-uFSH (n=45) almak üzere rastgele belirlendi. Ana sonuç ölçütleri; alınan olgun oosit sayısı, embriyo kalitesi, gebelik oranları, implantasyon oranlarıydı. Bulgular: Alınan olgun oosit sayısı, döllenme oranları, dondurularak saklanan embriyo sayısı r-FSH grubunda anlamlı olarak daha yüksek (sırasıyla p=0,024, p=0,023, p=0,026), aynı grupta kullanılan toplam FSH dozu ise anlamlı olarak daha düşüktü (p=0,023). Gebelik oranları, klinik gebelik oranları r-FSH grubunda istatistiksel olarak anlamlı olmamakla birlikte daha yüksekti (sırasıyla %52,2’ye karşı %35,6, p=0,11, %37’ye karşı %28,9, p=0,41). Klinik gebelik başına genel tedavi maliyetleri, r-FSH grubunda %9,94’lük bir artışla ilişkilendirilirken, gebelik başına maliyetler gruplar arasında farklı değildi. Sonuç: r-FSH, PCOS’de fertilizasyon oranları, alınan olgun oosit sayısı ve dondurularak saklanan embriyolar, gebelik oranları açısından HPuFSH'den üstündür, ancak klinik gebelik başına genel tedavi maliyetleri daha yüksektir.

🔖

Cite This Article

AYNIOĞLU, Ö., CEYLAN, Y., AKAR, B., ÇALIŞKAN, E., DOĞER, E., ÇAKIROĞLU, Y., ÖZKAN, S. Ö. (2022). Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study. Bağcılar Tıp Bülteni, Cilt: 7 - Sayı: 1, 63–69. https://ajindex.com/articles/648833

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Szilágyi A, Bártfai G, Mánfai A, Koloszár S, Pál A, Szabó I. Low-dose ovulation induction with urinary gonadotropins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynecol Endocrinol 2004;18(1):17-22.
  2. Aboulghar M, Saber W, Amin Y, Aboulghar M, Mansour R, Serour G. Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome. Fertil Steril 2010;94(6):2332-2334.
  3. Lenton E, Soltan A, Hewitt J, Thomson A, Davies W, Ashraf N, et al. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP). Hum Reprod 2000;15(5):1021-1027.
  4. Romeu A, Balasch J, Ruiz Balda JA, Barri PN, Daya S, Auray JP, et al. Cost-effectiveness of recombinant versus urinary follicle stimulating hormone in assisted reproduction techniques in the Spanish public health care system. J Assist Reprod Genet 2003;20(8):294-300.
  5. Gerli S, Casini ML, Unfer V, Costabile L, Mignosa M, Di Renzo GC. Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost-effectiveness. Reprod Biomed Online 2004;9(5):494-499.
  6. Pacchiarotti A, Aragona C, Gaglione R, Selman H. Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle. J Assist Reprod Genet 2007;24(9):400-405.
  7. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod 1999;14(9):2207-2215.
  8. Out HJ, Mannaerts BM, Driessen SG, Bennink HJ. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod 1995;10(10):2534-2540.
  9. Out HJ, Driessen SG, Mannaerts BM, Coelingh Bennink HJ. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997;68(1):138-142.
  10. Bergh C, Howles CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in w